Terms: = Ovarian cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Clinical Outcome
4 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. An integration analysis of mRNAs and miRNAs microarray data to identify key regulators for ovarian endometriosis based on competing endogenous RNAs.
Wang K; Sun Y; Wang Y; Liu L
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():468-475. PubMed ID: 32738676
[TBL] [Abstract] [Full Text] [Related]
3. Influence of p53 Isoform Expression on Survival in High-Grade Serous ovarian cancers.
Bischof K; Knappskog S; Hjelle SM; Stefansson I; Woie K; Salvesen HB; Gjertsen BT; Bjorge L
Sci Rep; 2019 Mar; 9(1):5244. PubMed ID: 30918304
[TBL] [Abstract] [Full Text] [Related]
4. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract] [Full Text] [Related]
